Early identification of germline mutation carriers may be relevant for the optimal management of prostate cancer and to inform cancer risk in relatives. However, population minorities have limited access to genetic testing. The aim of this study was to describe the frequency of DNA repair gene pathogenic variants (PVs) among Mexican men with prostate cancer referred for Genomic Cancer Risk Assessment and testing.
Patients diagnosed with prostate cancer who meet criteria for genetic testing and enrolled in the Clinical Cancer Genomics Community Research Network at the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán in Mexico City were included. Descriptive statistics were performed using frequency and proportions for categorical variables and median and range for quantitative variables. X2 and t test were used for group comparisons.
A total of 199 men were enrolled, median age at diagnosis was 66 (range 44-88) years; 45% were de novo metastatic and 44% were high- very high and 10% were intermediate risk group. Four (2%) had a pathogenic germline variant; one each of the following genes: ATM, CHEK2, BRIP1, and MUTYH (all monoallelic). Younger men at diagnosis were more likely to carry a PV than older age at diagnosis (56.7 vs. 66.4 years, P = .01).
Our results showed a low prevalence of known prostate cancer associated PVs and no BRCA PVs in Mexican men with prostate cancer. This suggests that the genetic and/or epidemiologic risk factors for prostate cancer are not well characterized in this specific population.
Clinical genitourinary cancer. 2023 May 23 [Epub ahead of print]
Yanin Chávarri-Guerra, María T Bourlon, José L Rodríguez-Olivares, Luis Orozco, Deborah Bazua, Andrés Rodríguez-Faure, Mirza J Alcalde-Castro, Elena Castro, Danielle Castillo, Josef Herzog, Jeffrey Weitzel
Department of Hematology and Oncology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico., Hemato-Oncology Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico., Centro Médico del Instituto de Seguridad Social del Estado de México y Municipios (ISSEMyM), Toluca, Edo. de México, Mexico., Facultad de Medicina, Universidad Autónoma de Baja California, Mexicali, Baja California, Mexico., Department of Medicine, Divisions of Palliative Medicine and Medical Oncology, University of Toronto, Toronto, Canada., National Cancer Research Center, Prostate Cancer Clinic Unit, Madrid, Spain., City of Hope Cancer Center, Latin American School of Oncology (ELO), Duarte, CA, United States., Latin American School of Oncology, Sierra Madre, CA. Electronic address: .